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SIRT1 orthologs extend life span in yeast, worms, ies, and mice.  SIRT1 also protects against metabolic disorders, such 
as obesity, insulin resistance, and hepatic steatosis, as well as aging-related neuronal diseases, by deacetylating histones 
and many transcription factors and cofactors. 
SIRT2 primarily resides in cytoplasm but also relocates to nucleus upon stress and during mitosis. Nuclear SIRT2 
deacetylates histones and various transcription factors and regulates cell-cycle progression and cell differentiation. 
SIRT2 also regulates various metabolic enzymes in the cytosol.
The major mitochondrial deacetylase SIRT3 affects acetylation of hundreds of mitochondrial proteins and regulates many 
metabolic enzymes through deacetylation, including LCAD (β-oxidation). SIRT3 KO mice develop hepatic steatosis and
insulin resistance on high-fat diet. SIRT3 also acts as a tumor suppressor by reducing ROS and its loss reprograms 
cellular metabolism in various human cancers.
SIRT4 is involved in amino acid metabolism by ADP-ribosylating GDH. SIRT4 KO mice manifest hyperinsulinemia due to 
the constitutive activation of GDH. SIRT4 is also a tumor suppressor and regulates glutamine metabolism in cancer cells 
via GDH. SIRT4 KO mice are prone to lung cancer.
Loss of SIRT5 leads to hypersuccinylation and malonylation of mitochondrial proteins and inhibition of β-oxidation and 
ketogenesis. SIRT5 KO mice also manifest elevated ammonia level due to the lack of CPS1 activation during fasting.
Overexpression of SIRT6 extends life span in mice.  Deletion of SIRT6 results in hypoglycemia and aging-like phenotypes 
in mice, including lymphopenia, kyphosis, and loss of fat pads. SIRT6 has various roles in transcription, genome stability, 
and metabolic regulation. SIRT6 efciently removes long-chain fatty acids from lysine and thus promotes TNFα secretion. 
SIRT6 acts as a corepressor for HIF-1α and cMYC and, thus, inhibits tumorigenesis.
In cancer cells, SIRT7 deacetylates H3K18 and represses the transcription of tumor-suppressor genes. 
SIRT7 is also involved in lipid metabolism, and SIRT7 KO mice are resistant to diet-induced obesity and fatty liver.
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Massachusetts Institute of Technology, Cambridge, MA 02139, USAThe yeast SIR2 gene was initially found to slow aging, and this protein and the mammalian ortholog SIRT1 were soon shown to function as NAD-dependent deacetylases that 
alter activities of their substrate proteins. SIR2 orthologs slow aging in multiple species. The seven mammalian sirtuins show homology across their catalytic and NAD-binding 
domains. These proteins have various deacylase activities in addition to deacetylation, including the removal of succinyl, malonyl (SIRT5), and long-chain fatty acid acyl esters 
(SIRT6) from lysines. Substrates of nuclear sirtuins include histones but also nuclear transcription factors and cofactors. In addition, all seven sirtuins deacylate many metabolic 
enzymes. In particular, mitochondrial sirtuins play key roles in deacylating and activating enzymes involved in fatty acid oxidation, the TCA cycle, and other oxidative pathways. 
Of note, SIRT3 is the only known mitochondrial deacetylase and confers neuroprotection. 
Physiological Effects of Deacetylation by Sirtuins 
One major outcome is the repression of glycolytic metabolism and the activation of oxidative metabolism. This includes activation of mitochondrial defense systems against 
reactive oxygen species and protein unfolding. This metabolic strategy is accentuated when energy is limiting, for example on a diet of calorie restriction (CR).
It was reported by some labs that SIR2 may not be necessary for the effects of CR in yeast. Technical reasons might account for these lab-to-lab differences, which may 
include variations in CR conditions or strain-specific differences. In mammals, the case that sirtuins mediate effects of CR is very strong, since sirtuins are activated by this diet 
and their absence abolishes many effects of CR, including longevity. 
A very interesting recent development in the field is that the NAD cosubstrate may play an important role in aging since NAD levels decline with aging in many organisms 
leading to a decline in sirtuins’ activities. Importantly, supplementation with NAD precursors can ameliorate or reverse the effects of aging in old mice or worms. The reasons 
underlying the decline in NAD with aging are not fully understood, but PARP-1 inhibition prevents NAD depletion, suggesting that accumulating nuclear DNA damage and PARP 
activation in aged animals may play a role in NAD depletion. Another possibility stems from the fact that the circadian clock drives NAD synthesis (and thus sirtuins’ activities), 
and the robustness of the clock declines with aging, perhaps leading to reduced NAD synthesis.  
Impact of Sirtuin Biology on Human Health 
First, several small molecule activators have been developed for SIRT1 and mitigate many of the diseases that are also improved by CR (diabetes, inflammation, cancer, cardio-
vascular disease, or osteoporosis). Since NAD levels fall with normal aging, supplementation with NAD precursors to restore “youthful” NAD levels may also offer a strategy to 
slow the effects of aging. Indeed, NAD supplementation and SIRT1 activation may well provide synergistic effects. Second, SIRT3, SIRT4, or SIRT6 may help drive cancer cell 
metabolism, since loss of SIRT3 or SIRT6 favors glycolytic metabolism (the Warburg effect) and loss of SIRT4 promotes glutamine metabolism, both hallmarks of tumor cells. 
Indeed, roughly 20%–40% of numerous human tumors show gene loss of otherwise reduced expression of SIRT3, SIRT4, or SIRT6. 
Future Directions  
Sirtuins also link metabolism, NAD, and the potential to affect gene expression by histone deacetylation. It will be important to study whether the environment (diet, stress, or 
exercise) impacts on the status of the epigenome via sirtuins. Such an interaction could provide an immediate link between lifestyle and physiology, perhaps influencing human 
health. Such effects on the epigenome may perdure, i.e., in the known effects of maternal environment during gestation on the health of the progeny. We may hope to find new 
ways of treating conditions in children or adults arising from epigenetic effects occurring in utero.
In summary, sirtuins are a unique class of NAD-dependent deacylases with many roles in cellular metabolism, health, and aging. It will be fascinating to follow how pharma-
cological approaches targeting sirtuin activities or the levels of NAD can be harnessed to improve human health. 
ABBREVIATIONS
CtIP, CtBP-interacting protein; G3BP, RNA-binding Ras-GAP SH3 binding protein; CRTC, CREB-regulated transcription coactivator; PPAR, peroxisome proliferator-activated recep-
tor; RARb, retinoic acid receptor b; PARP1, poly (ADP-ribose) polymerase 1; LXR, liver X receptors; FXR, farnesoid X receptor; HNF4a, hepatocyte nuclear factor 4a; HIF, hypoxia 
inducible factor; NBS1, Nijmegen breakage syndrome 1; XPA, xeroderma pigmentosum, complementation group A; WRN, Werner syndrome, RecQ helicase-like; CREB, cAMP 
responsive element binding protein: TFAM, transcription factor A, mitochondrial: Nhlh2, nescient helix loop helix 2; PGAM1, phosphoglycerate mutase 1; AceCS, acyl-CoA synthe-
tase; PTP1B, protein tyrosine phosphatase 1B; Mybbp1a, Myb-binding protein 1a; TFIIIC2, general transcription factor IIIC, polypeptide 2; GDH, glutamate dehydrogenase; MCD, 
malonyl-CoA decarboxylase; IDE, insulin-degrading enzyme; VCAD, long-chain Acyl-CoA dehydrogenase; VLCAD, very long-chain Acyl-CoA dehydrogenase; HMGCS2, 3-hydroxy-
3-methylglutaryl-CoA synthase 2; NDUFA9, NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 9; Skp2, S phase kinase-associated protein 2; SDHA, succinate dehydroge-
nase complex, subunit A; IDH2, isocitrate dehydrogenase 2; MRPL10, mitochondrial ribosomal protein L10; PDP1, pyruvate dehyrogenase phosphatase catalytic subunit 1; SOD, 
superoxide dismutase; CypD, cyclophilin D: OTC, ornithine carbamoyltransferase; OPA1, optic atrophy 1; PDH, pyruvate dehydrogenase; CPS1, carbamoyl-phosphate synthase 1; 
G6PD, glucose-6-phosphate dehydrogenase; LDH, lactate dehydrogenase; PEPCK1, phosphoenolpyruvate carboxykinase; ACYL, ATP citrate lyase; PRLR, prolactin receptor; MEK1, 
mitogen-activated protein kinase 1; ITPK1, inositol-tetrakisphosphate 1-kinase; S6K1, ribosomal protein S6 kinase polypeptide 1; Nampt, nicotinamide phosphoribosyltransferase; 
Nmnat, nicotinamide mononucleotide adenylyltransferase; NAPRT, nicotinic acid phosphoribosyltransferase; QAPRT, quinolinic acid phosphoribosyltransferase; NADS, NAD synthe-
tase; NNMT, nicotinamide N-methyltransferase; NRK, nicotinamid riboside kinase; L-Trp, L-tryptophan: NA, nicotinic acid; QA, quinolic acid; NAMN, nicotinic acid mononucleotide; 
NAAD, nicotinic acid adenine dinucleotide; NAD, nicotinamide adenine dinucleotide; NAM, nicotinamide; NMN, nicotinamide mononucleotide; NR, nicotinamide riboside; MNA, 
1-methylnicotinamide.
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